SAN DIEGO, June 11, 2025 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced new and updated clinical data from its FT819 program for the treatment of moderate-to-severe systemic lupus erythematosus $(SLE)$. The data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain. The initial clinical profile of the FT819 off-the-shelf CAR T-cell program showed significant disease improvement in all five patients dosed, with the first patient reaching a 12-month follow-up and demonstrating durable drug-free remission. The company is expanding its clinical footprint in the U.S. and Europe and plans to discuss registrational strategies with the FDA for FT819 under its Regenerative Medicine Advanced Therapy (RMAT) designation. Fate Therapeutics has approximately 450 cryopreserved drug product bags of FT819 in inventory for patient treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.